Hanx Biopharmaceuticals(03378.HK): Enters AI Drug R&D Collaboration with TwinEdge Bioscience

NewTimeSpace News: On July 2, 2026, Hanx Biopharmaceuticals (03378.HK) announced that its collaboration with Switzerland-based TwinEdge Bioscience has entered substantive research phase. The two parties will carry out translational medical research targeting core candidate drug HX009 with the support of artificial intelligence. TwinEdge has built personalized digital twin models based on mouse models of diffuse large B-cell lymphoma (DLBCL) and achieved preliminary research outcomes.

According to Hansoh Aitech, this cooperation is expected to refine patient screening protocols, consolidate early translational medical evidence for HX009 and optimize subsequent clinical pathway design. As the Company’s flagship asset, HX009 has recently completed proof-of-concept clinical study for EBV-positive non-Hodgkin lymphoma, with pivotal clinical trials scheduled to be initiated. The Company cautions that there is no guarantee the relevant product can be successfully developed and marketed eventually, and investors shall exercise prudence when trading the Company’s shares.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.